The emerging vaccines for malaria, dengue, Zika, HIV, Ebola, and other serotypes are expected to propel the market growth in the forthcoming years. In addition, the ongoing vaccination programs and the recommendation doses for respective vaccine in the developing and the under-developed countries have supplemented the market growth.
The report also profiles key players involved in the global vaccines market, such as Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Emergent Biosolutions, Inc., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Sanofi Pasteur, and Serum Institute of India Pvt. Ltd. They have adopted various strategies such as mergers & acquisitions, collaborations, partnerships, and others to gain a strong position in the industry.
The report states that the global vaccines market accounted for $31.2 Billion in 2016 and is anticipated to reach $65.1 Billion by 2023, registering a CAGR of 10.9% during the forecast period, 2017-2023.
High prevalence of diseases worldwide, surge in government focus towards immunization programs, and the emergence of technologically advanced vaccines drive the growth of the global vaccines market. Additionally, the prospect of high growth in emerging economies provides lucrative opportunities for emerging market players. However, high duration for vaccine production and high cost associated with it impede market growth.
Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/258
The report segments the global vaccines market by technology, indication, end use, and geography. Based on technology, the market is fragmented into conjugate vaccines, inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, and other vaccines. The recombinant vaccines segment is projected to exhibit the highest growth rate during the forecast period. Based on end use, the market is sub-segmented into pediatric vaccines, adult vaccines, and traveler vaccines. The pediatric vaccine segment accounted for nearly half of the global revenue in 2016, due to the high immunization rate among infants and adolescents.
Based on indication, the market is categorized into Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Diphtheria, Pertussis, & Tetanus (DTP), Polio, Hepatitis, Measles, Mumps, & Rubella (MMR), and Other Indications. The pneumococcal disease segment is expected to maintain its dominance during the forecast period, owing to the fact that Streptococcus pneumoniae (a pathogenic bacteria) is the leading cause of infectious diseases globally. However, human papilloma virus (HPV) segment is growing at the highest CAGR of 12.4% from 2017 to 2023, as it is the most common type of sexually transmitted disease, specifically in women, which causes cervical cancer, the fourth most common type of cancer prevailing in women. Regionally, North America dominated the global vaccines market in 2016. However, Asia-Pacific is poised to exhibit the highest growth rate of 12.0%, owing to the high demand for vaccination in densely populated areas, such as India and China.
Allied Market Research, a market research and advisory company of Allied Analytics LLP,
provides business insights and market research reports to large as well as small &
medium enterprises. The company assists its clients to strategize business policies and
achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection
to investment advice. The analysts at Allied Market Research dig out factors that help
clients to understand the significance and impact of market dynamics. The company
amplies client’s insight on the factors, such as strategies, future estimations, growth
or fall forecasting, opportunity analysis, and consumer surveys among others. As
follows, the company offers consistent business intelligent support to aid the clients
to turn into prominent business firm.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060